Effect of New Coumarin-Ferulate Cyclic Conjugates on Acute Kidney Injury (Oxalate Nephropathy): Synthesis, In Vitro...

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Nephrology

Background:

• Acute kidney injury (AKI) pathogenesis involves the TLR-4/NF-κB pathway, leading to pro-inflammatory cytokine release.
• Targeting these cytokines is a strategy for developing novel AKI therapeutics.
• Existing treatments for AKI have limitations, necessitating the search for new anti-inflammatory agents.

Purpose of the Study:

• To synthesize and characterize novel coumarin-ferulate cyclic conjugates.
• To evaluate the anti-inflammatory and renal protective potential of these compounds in AKI.
• To identify specific compounds effective against key inflammatory mediators in AKI.

Main Methods:

• Synthesis and characterization of ten coumarin-ferulate cyclic conjugates using oxidative coupling, mass spectrometry, and NMR spectroscopy.
• In vitro assessment of cytotoxicity and inhibition of TNF-α, IL-6, and IL-1β using RAW 264.7 cells and ELISA.
• In vivo evaluation in an oxalate-induced nephropathy mouse model, assessing renal function markers (BUN, creatinine), cytokine levels (Western blot, qRT-PCR), immune cell populations (flow cytometry), and kidney histopathology (H&E staining).

Main Results:

• Compounds 3 and 5 demonstrated significant inhibition of TNF-α, IL-6, and IL-1β secretion and IL-1β protein levels in vitro.
• In vivo studies showed that compounds 3 and 5 provided significant renal protection, reducing BUN and creatinine levels.
• Treatment with compounds 3 and 5 decreased renal IL-1β protein and TNF-α/IL-1β mRNA expression, reduced inflammatory immune cells, and ameliorated kidney tissue damage.

Conclusions:

• Novel coumarin-ferulate cyclic conjugates possess potent anti-inflammatory properties.
• Compounds 3 and 5 exhibit significant renal protective effects in an AKI model.
• These findings highlight the therapeutic potential of these novel conjugates for managing AKI.